Vivos Therapeutics Agrees to Acquire 11% Stake in SOD Sciences
Vivos Therapeutics agreed to acquire an 11% fully diluted stake in SOD Sciences and 50% co-ownership of its proprietary pseudohypoxia test. Consideration comprises 12,000 shares of Series C Convertible Preferred Stock with a $12 million aggregate stated value; no cash is payable. Preferred shares convert at $0.15 into